PD-L1 Methylation Restricts PD-L1/PD-1 Interactions to Control Cancer Immune Surveillance

Investigators showed that PD-L1 K162 methylation was a negative predictive marker for anti–PD-1 treatment in patients with non–small cell lung cancer, and showed that the PD-L1 K162 methylation:PD-L1 ratio was a more accurate biomarker for predicting anti–PD-(L)1 therapy sensitivity.